Glenmark to launch Leucovorin Calcium injection in December 2025 for cancer drug toxicity

Glenmark Pharmaceuticals Inc., USA has announced that it will launch Leucovorin Calcium for Injection USP, 350 mg per single dose vial, in December 2025.

Leucovorin Calcium is commonly used to reduce toxicity associated with certain cancer medications. Glenmark's product is bioequivalent and therapeutically equivalent to Hospira Inc.'s reference drug, Leucovorin Calcium for Injection, 350 mg/vial.

IQVIA data shows that the 350 mg/vial Leucovorin Calcium injection market generated around $16.8 million in sales in the twelve months ended October 2025.

Marc Kikuchi, President and Business Head, North America at Glenmark, said the upcoming launch strengthens the company's institutional portfolio and reinforces its commitment to offering high quality and affordable treatment alternatives.

Shares of Glenmark Pharmaceuticals Ltd. were trading 0.092% higher at ₹1,952.60 on Thursday, and the stock is up 21% so far in 2025.